Intracranial Activity of Deruxtecan-Based Antibody–Drug Conjugates in Non-Small Cell Lung Cancer Brain Metastases: A Systematic Review and Meta-Analysis of Prospective Trial Cohorts
- 1Department of Paediatric Neurosurgery, Children’s Hospital Named After Prof. Dr Med. Jan Bogdanowicz, Niekłańska 4/24, 03-924 Warsaw, Poland
- 2Faculty of Medicine, Lazarski University, Świeradowska 43, 02-662 Warsaw, Poland
- 3Department of Neurosurgery, Maria Skłodowska-Curie National Research Institute of Oncology, W.K. Roentgena 5, 02-781 Warsaw, Poland
Abstract
Background/Objectives: Brain metastases are common in advanced non-small cell lung cancer (NSCLC). Antibody–drug conjugates (ADCs) have shown intracranial activity in trial subgroups, but intracranial data had rarely been pooled. Methods: MEDLINE, Scopus, Web of Science, registries, and congress sources were searched through 21 September 2026 for prospective trials reporting central nervous system (CNS) outcomes of ADC monotherapy in NSCLC (PROSPERO CRD420261516140). Intracranial objective response rate (icORR) in measurable brain metastases was pooled with a random-intercept logistic model. Risk of bias and GRADE certainty were assessed. Results: Eight prospective cohorts (139 patients; six molecularly selected) of deruxtecan-based ADCs were included. Pooled icORR was 32% (95% CI, 25–41%; 45/139; I2 = 0%; prediction interval, 24–43%), and pooled intracranial disease control was 83% (69–92%; five cohorts). In TUXEDO-3, the only dedicated prospective CNS trial, restricted to active metastases, icORR was 30% (6/20). CNS progression-free survival hazard ratios versus chemotherapy were 0.48 (0.23–0.98) and 0.75 (0.53–1.06). Certainty was very low for single-arm response and low for comparative outcomes. Conclusions: Deruxtecan-based ADCs produced intracranial responses in one third of patients with measurable brain metastases from previously treated, predominantly oncogene-driven NSCLC, including active disease. Limited randomized data are compatible with delayed CNS progression. Prospective trials with CNS-specific endpoints are needed.
Related
- Efficacy and safety of antibody-drug conjugates in advanced small cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials
- Complete Response to First-Line Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Extra-axial Central Nervous System Metastases.
- Efficacy and Safety of Datopotamab Deruxtecan From a Single-Institution Experience in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer After Multiple Prior Therapies Including Antibody-Drug Conjugates.
- Peripheral immune-inflammatory markers associated with intracranial progression-free survival after Gamma Knife radiosurgery in patients with non-small cell lung cancer brain metastases: a retrospective cohort study.
- MRI-based intratumoral and peritumoral heterogeneity for predicting intracranial progression in EGFR-mutant lung adenocarcinoma patients with treatment-naive brain metastases receiving first-line third-generation EGFR-TKIs.
BibTeX
@article{tykocki2026intracranial,
title = {{Intracranial Activity of Deruxtecan-Based Antibody–Drug Conjugates in Non-Small Cell Lung Cancer Brain Metastases: A Systematic Review and Meta-Analysis of Prospective Trial Cohorts}},
author = {Tomasz Tykocki and Krzysztof Szalecki},
journal = {Cancers},
year = {2026},
month = nov,
doi = {10.3390/cancers18213552},
url = {https://www.mdpi.com/2072-6694/18/21/3552},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Intracranial Activity of Deruxtecan-Based Antibody–Drug Conjugates in Non-Small Cell Lung Cancer Brain Metastases: A Systematic Review and Meta-Analysis of Prospective Trial Cohorts
AU - Tomasz Tykocki
AU - Krzysztof Szalecki
PY - 2026
DA - 2026/11/05
JO - Cancers
DO - 10.3390/cancers18213552
UR - https://www.mdpi.com/2072-6694/18/21/3552
AB - Background/Objectives: Brain metastases are common in advanced non-small cell lung cancer (NSCLC). Antibody–drug conjugates (ADCs) have shown intracranial activity in trial subgroups, but intracranial data had rarely been pooled. Methods: MEDLINE, Scopus, Web of Science, registries, and congress sources were searched through 21 September 2026 for prospective trials reporting central nervous system (CNS) outcomes of ADC monotherapy in NSCLC (PROSPERO CRD420261516140). Intracranial objective response rate (icORR) in measurable brain metastases was pooled with a random-intercept logistic model. Risk of bias and GRADE certainty were assessed. Results: Eight prospective cohorts (139 patients; six molecularly selected) of deruxtecan-based ADCs were included. Pooled icORR was 32% (95% CI, 25–41%; 45/139; I2 = 0%; prediction interval, 24–43%), and pooled intracranial disease control was 83% (69–92%; five cohorts). In TUXEDO-3, the only dedicated prospective CNS trial, restricted to active metastases, icORR was 30% (6/20). CNS progression-free survival hazard ratios versus chemotherapy were 0.48 (0.23–0.98) and 0.75 (0.53–1.06). Certainty was very low for single-arm response and low for comparative outcomes. Conclusions: Deruxtecan-based ADCs produced intracranial responses in one third of patients with measurable brain metastases from previously treated, predominantly oncogene-driven NSCLC, including active disease. Limited randomized data are compatible with delayed CNS progression. Prospective trials with CNS-specific endpoints are needed.
SN - 2072-6694
ER -